KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Boston Scientific (BSX) Profit After Tax (2016 - 2025)

Boston Scientific (BSX) has disclosed Profit After Tax for 17 consecutive years, with $670.0 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 19.22% to $670.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 billion through Dec 2025, up 56.75% year-over-year, with the annual reading at $2.9 billion for FY2025, 56.66% up from the prior year.
  • Profit After Tax hit $670.0 million in Q4 2025 for Boston Scientific, down from $755.0 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $795.0 million in Q2 2025 to a low of $95.0 million in Q4 2021.
  • Historically, Profit After Tax has averaged $403.4 million across 5 years, with a median of $380.0 million in 2021.
  • Biggest five-year swings in Profit After Tax: skyrocketed 3000.0% in 2021 and later tumbled 67.74% in 2022.
  • Year by year, Profit After Tax stood at $95.0 million in 2021, then skyrocketed by 47.37% to $140.0 million in 2022, then surged by 260.0% to $504.0 million in 2023, then grew by 11.51% to $562.0 million in 2024, then rose by 19.22% to $670.0 million in 2025.
  • Business Quant data shows Profit After Tax for BSX at $670.0 million in Q4 2025, $755.0 million in Q3 2025, and $795.0 million in Q2 2025.